Omeicos Therapeutics, a biopharmaceutical spinout of research institute Max Delbrück Center for Molecular Medicine, achieved a first close of its series B round at €8.3m ($8.7m) on Wednesday.
The round was co-led by Vesalius Biocapital and plant construction company SMS Group.
German state-owned development bank KFW and public-private partnership High-Tech Gründerfonds (HTGF) and Ascension, a tech transfer office for a range of German universities, hospitals and institutes, also participated, as did VC Fonds Technologie Berlin, Falck Revocable Trust…